Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis

Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs), which may result in treatment discontinuation. We sought to describe the onset, frequency, and kinetics of irAEs melanoma patients a real-life setting further investigate prognostic role outcomes. In this retrospective single-center cohort study, we included 249 patients. Onset, grade, resolution their were analyzed. A total 191 (74.6%) non-adjuvant 65 (25.3%) adjuvant identified. setting, 29 (59.2%) with anti-CTLA4, 43 (58.1%) anti-PD1, 54 (79.4%) anti-PD1/anti-CTLA4 experienced some grade irAE these had an improved outcome. frequency was 84.6% anti-CTLA4 63.5% but no correlation disease relapse observed. Patients underlying autoimmune conditions have risk exacerbation. Immunomodulatory agents impact on efficacy. IrAEs are correlated increased efficacy setting. Application steroids immunomodulatory agents, such as anti-TNF-alpha or anti-IL6, did not affect ICI These data support possible markers for treatment.